FIELD: medicine.
SUBSTANCE: invention refers to a compound having the structure of formula (I), or its pharmaceutically acceptable salt, 
wherein specified radicals are presented in the description, and also concerns a compound representing 
or its pharmaceutically acceptable salt. The present invention declares a pharmaceutical composition possessing inhibitory activity in the relation to 20S proteasome containing a pharmaceutically acceptable carrier or a diluent and a therapeutically effective amount of the compound, and also the invention refers to methods of treating the immune diseases, such as inflammatory intestinal disease, to treating cancer, to treating infection, to treating proliferative diseases, to treating neurodegenerative disease or asthma.
EFFECT: higher clinical effectiveness.
34 cl, 21 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ENZYME INHIBITING COMPOUNDS | 2005 |
|
RU2384585C2 |
| NEPRILYSIN INHIBITORS | 2012 |
|
RU2629930C2 |
| NOVEL CONDENSED PYRIDINE DERIVATIVES USED AS C-MET TYROSINE KINASE INHIBITORS | 2013 |
|
RU2619130C2 |
| ENZYME-INHIBITING COMPOUNDS | 2006 |
|
RU2453556C2 |
| SUBSTITUTED QUINAZINE DERIVATIVES AS FGFR-KINASE INHIBITORS FOR TREATMENT OF CANCER | 2011 |
|
RU2602233C2 |
| ANTI-CANCER BENZOPYRAZINES ACTING THROUGH FGFR-KINASES INHIBITION | 2012 |
|
RU2639863C2 |
| M1 MUSCARINE RECEPTOR AGONISTS FOR ANALGETIC THERAPY | 2004 |
|
RU2358735C2 |
| LEVODOP PRODRUGS, BASED ON THEM COMPOSITIONS AND THEIR APPLICATION | 2005 |
|
RU2365580C2 |
| NEPRILYSIN INHIBITORS | 2011 |
|
RU2605557C2 |
| MAGL INHIBITORS | 2017 |
|
RU2754536C1 |
